<DOC>
	<DOC>NCT00619736</DOC>
	<brief_summary>This study will provide an initial assessment of the safety, tolerability and pharmacokinetics (PK) of NSA-789 after administration of ascending single oral doses to healthy Japanese male subjects. This is a randomized, double-blind, placebo-controlled, inpatient, sequential-group study conducted under fasting conditions at a single investigational site. Each subject will participate in only 1 dose group and will receive only 1 dose of test article.</brief_summary>
	<brief_title>Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<criteria>Men aged 20 to 45 years inclusive at screening. Healthy as determined by the investigator on the basis of screening evaluations. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. Use of any investigational drug within 90 days before study day 1 or prescription drug within 30 days before study day 1 Any clinically important deviation from normal limits in physical examination, vital signs, 12lead electrocardiograms (ECGs), or clinical laboratory test results.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Healthy</keyword>
</DOC>